P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib
Subrata Ghosh(University College Cork), Julián Panés(Hospital Clínic de Barcelona), Walter Reinisch(Medical University of Vienna), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Édouard Louis(Centre Hospitalier Universitaire de Liège), Edward V. Loftus(Mayo Clinic), Fabio Cataldi(Pfizer (United States))
Cited by 6
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k